Clinical Trial Update: Studying TAK-243 in Patients With Advanced Cancer [Phase 1]

View source ↗

Summary

This entry describes a Phase 1 clinical trial evaluating TAK-243 in adults with advanced cancers, including non-Hodgkin lymphoma and various malignant solid tum…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma
• Malignant Solid Tumor
• Non-hodgkin Lymphoma

Drugs mentioned

• TAK-243 (Ubiquitin-activating enzyme E1 inhibitor TAK-243)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 1 | Status: RECRUITING